Repligen

Q2 FY2026 EarningsQ2 FY26 revenue reached $204M, up 12% YoY and 13% organic, reflecting sequential acceleration. Adjusted operating income surged 55% YoY to $34M, with adjusted operating margin expanding 4.7pct to 16.7%. Adjusted EPS rose 46% YoY to $0.54. Management raised FY26 organic growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, citing strong order momentum and the strategic acquisition of BioLife Solutions.